OBJECTIVE: The risk of stroke in patients with recently symptomatic carotid stenosis is considerably higher than in patients with asymptomatic stenosis. In the present study it was hypothesised that excessive platelet activation might partly contribute to this difference. METHODS: A full blood count was done and whole blood flow cytometry used to measure platelet surface expression of CD62P, CD63, and PAC1 binding and the percentage of leucocyte-platelet complexes in patients with acute (0-21 days, n = 19) and convalescent (79-365 days) symptomatic (n = 16) and asymptomatic (n = 16) severe (> or =70%) carotid stenosis. Most patients were treated with aspirin (37.5-300 mg daily) although alternative antithrombotic regimens were more commonly used in the symptomatic group. RESULTS: The mean platelet count was higher in patients with acute and convalescent symptomatic compared with asymptomatic carotid stenosis. There were no significant differences in the median percentage expression of CD62P and CD63, or PAC1 binding between the acute or convalescent symptomatic and asymptomatic patients. The median percentages of neutrophil-platelet (p = 0.004), monocyte-platelet (p = 0.046), and lymphocyte-platelet complexes (p = 0.02) were higher in acute symptomatic than in asymptomatic patients. In patients on aspirin monotherapy, the percentages of neutrophil-platelet and monocyte-platelet complexes (p = 0.03) were higher in acute symptomatic (n = 11) than asymptomatic patients (n = 14). In the convalescent phase, the median percentages of all leucocyte-platelet complexes in the symptomatic group dropped to levels similar to those found in the asymptomatic group. CONCLUSION: Increased platelet count and leucocyte-platelet complex formation may contribute to the early excess risk of stroke in patients with recently symptomatic carotid stenosis.
OBJECTIVE: The risk of stroke in patients with recently symptomatic carotid stenosis is considerably higher than in patients with asymptomatic stenosis. In the present study it was hypothesised that excessive platelet activation might partly contribute to this difference. METHODS: A full blood count was done and whole blood flow cytometry used to measure platelet surface expression of CD62P, CD63, and PAC1 binding and the percentage of leucocyte-platelet complexes in patients with acute (0-21 days, n = 19) and convalescent (79-365 days) symptomatic (n = 16) and asymptomatic (n = 16) severe (> or =70%) carotid stenosis. Most patients were treated with aspirin (37.5-300 mg daily) although alternative antithrombotic regimens were more commonly used in the symptomatic group. RESULTS: The mean platelet count was higher in patients with acute and convalescent symptomatic compared with asymptomatic carotid stenosis. There were no significant differences in the median percentage expression of CD62P and CD63, or PAC1 binding between the acute or convalescent symptomatic and asymptomatic patients. The median percentages of neutrophil-platelet (p = 0.004), monocyte-platelet (p = 0.046), and lymphocyte-platelet complexes (p = 0.02) were higher in acute symptomatic than in asymptomatic patients. In patients on aspirin monotherapy, the percentages of neutrophil-platelet and monocyte-platelet complexes (p = 0.03) were higher in acute symptomatic (n = 11) than asymptomatic patients (n = 14). In the convalescent phase, the median percentages of all leucocyte-platelet complexes in the symptomatic group dropped to levels similar to those found in the asymptomatic group. CONCLUSION: Increased platelet count and leucocyte-platelet complex formation may contribute to the early excess risk of stroke in patients with recently symptomatic carotid stenosis.
Authors: A Celi; G Pellegrini; R Lorenzet; A De Blasi; N Ready; B C Furie; B Furie Journal: Proc Natl Acad Sci U S A Date: 1994-09-13 Impact factor: 11.205
Authors: Dominick J H McCabe; Paul Harrison; Ian J Mackie; Paul S Sidhu; Gordon Purdy; Andrew S Lawrie; Hilary Watt; Martin M Brown; Samuel J Machin Journal: Br J Haematol Date: 2004-06 Impact factor: 6.998
Authors: W O Tobin; J A Kinsella; G F Kavanagh; J S O'Donnell; R T McGrath; T Coughlan; D R Collins; D O'Neill; B Egan; S Tierney; T M Feeley; R P Murphy; D J H McCabe Journal: J Neurol Date: 2014-04-30 Impact factor: 4.849
Authors: N Matijevic; K K Wu; A G Howard; B Wasserman; W Y-W Wang; A R Folsom; A R Sharrett Journal: Cerebrovasc Dis Date: 2011-04-12 Impact factor: 2.762
Authors: Stephen J Murphy; Soon T Lim; Justin A Kinsella; Sean Tierney; Bridget Egan; Tim M Feeley; Clare Dooley; James Kelly; Sinead M Murphy; Richard A Walsh; Ronan Collins; Tara Coughlan; Desmond O'Neill; Joseph A Harbison; Prakash Madhavan; Sean M O'Neill; Mary P Colgan; Jim F Meaney; George Hamilton; Dominick Jh McCabe Journal: J Cereb Blood Flow Metab Date: 2019-11-11 Impact factor: 6.200
Authors: S J X Murphy; S T Lim; J A Kinsella; S Tierney; B Egan; T M Feeley; S M Murphy; R A Walsh; D R Collins; T Coughlan; D O'Neill; J A Harbison; P Madhavan; S M O'Neill; M P Colgan; D Cox; N Moran; G Hamilton; J F Meaney; D J H McCabe Journal: J Neurol Date: 2019-10-12 Impact factor: 4.849
Authors: W O Tobin; J A Kinsella; G F Kavanagh; J S O'Donnell; R A McGrath; D R Collins; T Coughlan; D O'Neill; B Egan; S Tierney; T M Feeley; R P Murphy; Dominick J H McCabe Journal: J Neurol Date: 2012-10-14 Impact factor: 4.849
Authors: O Dotsenko; N Chaturvedi; S A McG Thom; A R Wright; J Mayet; A Shore; C Schalkwijk; A D Hughes Journal: J Thromb Haemost Date: 2007-10 Impact factor: 5.824